248 related articles for article (PubMed ID: 21849418)
1. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
Marchion DC; Cottrill HM; Xiong Y; Chen N; Bicaku E; Fulp WJ; Bansal N; Chon HS; Stickles XB; Kamath SG; Hakam A; Li L; Su D; Moreno C; Judson PL; Berchuck A; Wenham RM; Apte SM; Gonzalez-Bosquet J; Bloom GC; Eschrich SA; Sebti S; Chen DT; Lancaster JM
Clin Cancer Res; 2011 Oct; 17(19):6356-66. PubMed ID: 21849418
[TBL] [Abstract][Full Text] [Related]
2. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.
Chon HS; Marchion DC; Xiong Y; Chen N; Bicaku E; Stickles XB; Bou Zgheib N; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Lancaster JM
Gynecol Oncol; 2012 Jan; 124(1):119-24. PubMed ID: 22032837
[TBL] [Abstract][Full Text] [Related]
3. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin.
Bansal N; Marchion DC; Bicaku E; Xiong Y; Chen N; Stickles XB; Sawah EA; Wenham RM; Apte SM; Gonzalez-Bosquet J; Judson PL; Hakam A; Lancaster JM
J Gynecol Oncol; 2012 Jan; 23(1):35-42. PubMed ID: 22355465
[TBL] [Abstract][Full Text] [Related]
4. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.
Bou Zgheib N; Xiong Y; Marchion DC; Bicaku E; Chon HS; Stickles XB; Sawah EA; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Cubitt CL; Chen DT; Lancaster JM
Int J Oncol; 2012 Jul; 41(1):179-88. PubMed ID: 22552627
[TBL] [Abstract][Full Text] [Related]
5. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Al Sawah E; Chen X; Marchion DC; Xiong Y; Ramirez IJ; Abbasi F; Bou Zgheib N; Chon HS; Wenham RM; Apte SM; Judson PL; Lancaster JM
Gynecol Oncol; 2013 Oct; 131(1):207-12. PubMed ID: 23877012
[TBL] [Abstract][Full Text] [Related]
6. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.
Bicaku E; Xiong Y; Marchion DC; Chon HS; Stickles XB; Chen N; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Fulp W; Cubitt CL; Chen DT; Lancaster JM
Br J Cancer; 2012 Jun; 106(12):1967-75. PubMed ID: 22596241
[TBL] [Abstract][Full Text] [Related]
7. Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.
Boac BM; Xiong Y; Marchion DC; Abbasi F; Bush SH; Ramirez IJ; Khulpateea BR; Clair McClung E; Berry AL; Bou Zgheib N; Chon HS; Shahzad MM; Judson PL; Wenham RM; Apte SM; Berglund AE; Magliocco AM; Lancaster JM
Gynecol Oncol; 2016 Feb; 140(2):259-63. PubMed ID: 26731723
[TBL] [Abstract][Full Text] [Related]
8. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
9. The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest.
Al Sawah E; Marchion DC; Xiong Y; Ramirez IJ; Abbasi F; Boac BM; Bush SH; Bou Zgheib N; McClung EC; Khulpateea BR; Berry A; Hakam A; Wenham RM; Lancaster JM; Judson PL
J Cancer Res Clin Oncol; 2015 Feb; 141(2):237-42. PubMed ID: 25164128
[TBL] [Abstract][Full Text] [Related]
10. BAD-mediated apoptotic pathway is associated with human cancer development.
Stickles XB; Marchion DC; Bicaku E; Al Sawah E; Abbasi F; Xiong Y; Bou Zgheib N; Boac BM; Orr BC; Judson PL; Berry A; Hakam A; Wenham RM; Apte SM; Berglund AE; Lancaster JM
Int J Mol Med; 2015 Apr; 35(4):1081-7. PubMed ID: 25653146
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
12. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
13. The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance.
Manzoor HB; Asare-Werehene M; Pereira SD; Satyamoorthy K; Tsang BK
J Ovarian Res; 2024 Jan; 17(1):15. PubMed ID: 38216951
[TBL] [Abstract][Full Text] [Related]
14. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.
Musiani D; Hammond DE; Cirillo L; Erriquez J; Olivero M; Clague MJ; Di Renzo MF
J Proteome Res; 2014 Nov; 13(11):4970-82. PubMed ID: 25099161
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
Yoshihara M; Kajiyama H; Yokoi A; Sugiyama M; Koya Y; Yamakita Y; Liu W; Nakamura K; Moriyama Y; Yasui H; Suzuki S; Yamamoto Y; Ricciardelli C; Nawa A; Shibata K; Kikkawa F
Int J Cancer; 2020 Apr; 146(8):2268-2280. PubMed ID: 31904865
[TBL] [Abstract][Full Text] [Related]
16. The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.
Stronach EA; Cunnea P; Turner C; Guney T; Aiyappa R; Jeyapalan S; de Sousa CH; Browne A; Magdy N; Studd JB; Sriraksa R; Gabra H; El-Bahrawy M
Oncotarget; 2015 Oct; 6(31):31593-603. PubMed ID: 26267317
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
18. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
19. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients.
Liu R; Zeng Y; Zhou CF; Wang Y; Li X; Liu ZQ; Chen XP; Zhang W; Zhou HH
Sci Rep; 2017 Feb; 7(1):18. PubMed ID: 28154416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]